Literature DB >> 29166574

Altered TNF-α response by Aconibal® and methotrexate in a lipopolysaccharide-induced setting of inflammatory conditions: Potential on a synergistic combination.

Gunhyuk Park1, Seung Hoon Lee2, Ji-Ye Han3, Dal-Seok Oh4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Aconitum carmichaelii (AC) is a common herbal medicine used as anti-inflammatory and analgesic agent in Eastern Asia. In Korea, a commercial processed AC (Aconibal®) is traditionally used to treat the symptoms of spondylosis deformans and rheumatic pain.
AIM OF STUDY: Rheumatoid arthritis (RA) is systemic and autoimmune disease characterized by chronic inflammation. Methotrexate (MTX) is often the first-line therapy for RA. If MTX monotherapy is ineffective or RA is initially severe, adding a tumor necrosis factor alpha (TNF-α) inhibitor to the treatment can be beneficial. However, its inhibitory effects on RA when combined with MTX are unknown. Therefore, we investigated the stable modulation of and synergistic to additive effect on TNF-α using AC combined with MTX (AMC).
MATERIALS AND METHODS: An inflammatory response mimicking RA was induced in the mouse macrophage cell line Raw 264.7 using interferon-γ or lipopolysaccharide (LPS). We predicted that AC and MTX at a 3:1 ratio would have synergistic therapeutic effects and this was determined using the Chou-Talalay method of median effect analysis and CalcuSyn software. We analyzed the profiles of various inflammatory cytokine-related proteins using Search tool for retrieval of interacting genes and Kyoto Encyclopedia of Genes and Genomes.
RESULTS: The expression levels of selected inflammatory immune mediators such as interleukin (IL)-6, IL-1α, chemokine ligand 5, granulocyte-colony stimulating factor, nitric oxide synthase, and cyclooxygenase were reduced via regulation of the mitogen-activated protein kinase signaling pathway. AMC inhibited the levels of matrix metalloproteinases-1 and -3 in the human synovial cell line SW982.
CONCLUSIONS: Our data show for the first time the potential beneficial effects of AMC in RA management.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aconitum carmichaelii; Cytokine; Inflammation; Methotrexate; Synergy; TNF-α

Mesh:

Substances:

Year:  2017        PMID: 29166574     DOI: 10.1016/j.jep.2017.11.020

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  Hematological and Histopathological Effects of Subacute Aconitine Poisoning in Mouse.

Authors:  Hao Lu; Li Mei; Ziyu Guo; Kexin Wu; Yunhao Zhang; Shiyu Tang; Yiru Zhu; Baoyu Zhao
Journal:  Front Vet Sci       Date:  2022-04-05

2.  Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients.

Authors:  Sandro C Furiati; Jonatas S Catarino; Marcos V Silva; Rafaela F Silva; Rayane B Estevam; Reginaldo B Teodoro; Sanivia L Pereira; Meire Ataide; Virmondes Rodrigues; Denise B R Rodrigues
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

3.  Phytochemical and In-Vivo Anti-Arthritic Significance of Aloe thraskii Baker in Combined Therapy with Methotrexate in Adjuvant-Induced Arthritis in Rats.

Authors:  Rania M Kamal; Manal M Sabry; Zeinab Y Aly; Mohamed S Hifnawy
Journal:  Molecules       Date:  2021-06-15       Impact factor: 4.411

4.  Protective effect of Palmijihwanghwan in a mouse model of cigarette smoke and lipopolysaccharide-induced chronic obstructive pulmonary disease.

Authors:  Eun Bok Baek; Jin-Hyung Rho; Eunhye Jung; Chang-Seob Seo; Jin-Hee Kim; Hyo-Jung Kwun
Journal:  BMC Complement Med Ther       Date:  2021-11-16

5.  Efficacy, safety, and cost-effectiveness analysis of adjuvant herbal medicine treatment, Palmijihwang-hwan, for chronic low back pain: a study protocol for randomized, controlled, assessor-blinded, multicenter clinical trial.

Authors:  Won-Suk Sung; Sae-Rom Jeon; Ye-Jin Hong; Tae-Hun Kim; Seungwon Shin; Hyun-Jong Lee; Byung-Kwan Seo; Yeon-Cheol Park; Eun-Jung Kim; Dong-Woo Nam
Journal:  Trials       Date:  2019-12-27       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.